Contact:
4008465777
-
About Us
News & Events
-
06-21
Tonghua Dongbao: First Patient Dosed in Phase Ib Clinical Trial of Dual GLP-1/GIP Receptor Agonist (THDBH120 Injection) for Diabetes Indications
Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd., a wholly owned subsidiary of Tonghua Dongbao Pharmaceutical Co., Ltd. ("the Company"), received the notice of approval from the Center for Drug E...
-
05-15
Tonghua Dongbao Doses the First Patient in Phase I Clinical Trials of Insulin Degludec/Liraglutide Injection
Tonghua Dongbao Pharmaceutical Co., Ltd. ("Tonghua Dongbao" or "the Company") has initiated the Phase I clinical trials in China for Insulin Degludec/Liraglutide Injection following the receipt of a c...
-
05-08
Tonghua Dongbao Invests RMB 100 Million in JHM Biopharm for Strategic Expansion into Promising Sectors
On May 7, 2024, Tonghua Dongbao Pharmaceutical Co., Ltd. (hereafter referred to as "Tonghua Dongbao" or "the Company") entered into a Capital Increase Agreement with JHM Biopharm (Hangzhou) Co., Ltd. ...
-
05-08
Tonghua Dongbao Introduces GLP-1 Semaglutide Injection
Recently, Tonghua Dongbao Pharmaceutical Co., Ltd. (hereinafter referred to as "Tonghua Dongbao" or "the Company") signed the Commercialization Licensing and Marketing Authorization Holder (MAH) Agree...
-
05-07
Tonghua Dongbao: First Patient Dosed in Phase IIa Clinical Trial of Dual Inhibitor for Gout (THDBH151 Tablets)
Recently, Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd., a wholly owned subsidiary of Tonghua Dongbao Pharmaceutical Co., Ltd. (hereafter referred to as "Tonghua Dongbao" or "the Company") suc...
-
04-27
Tonghua Dongbao Releases 2024 Q1 Report
On April 26, Tonghua Dongbao Pharmaceutical Co., Ltd. (stock code: 600867, hereinafter referred to as "Tonghua Dongbao" or “the Company") released its 2024 Q1 report. During the reporting period, the...